Roche Holding AG

ROG

CH0012032048

Pharmaceuticals

Market Closed - Swiss Exchange Other stock markets 11:30:49 2024-04-23 am EDT			5-day change	1st Jan Change
229.7 ^CHF	+1.73%		+3.70%	-6.05%

Apr. 19	Swiss Equities Flash Green; Middle East Tensions Rise	MT
Apr. 19	Roche: approval in lung cancer in the United States	CF

ROCHE HOLDINGS AG : JP Morgan reiterates its Neutral rating

January 28, 2021 at 03:04 am EST

Initially Neutral on the company, JP Morgan's analyst Richard Vosser maintained his recommendation. The target price remains unchanged at CHF 345.

Latest news about Roche Holding AG

Swiss Equities Flash Green; Middle East Tensions Rise	Apr. 19	MT
Roche: approval in lung cancer in the United States	Apr. 19	CF
Nykode Therapeutics Launches Phase 2 Clinical Trial for Cervical Cancer Vaccine	Apr. 19	MT
Roche's Lung-Cancer Drug Alecensa Gets New FDA Approval	Apr. 19	DJ
Roche's Early-stage Lung Cancer Treatment Alecensa Wins US FDA Nod	Apr. 19	MT
FDA Approves Roche?s Alecensa as the First Adjuvant Treatment for People with ALK-Positive Early-Stage Lung Cancer	Apr. 19	CI
Roche's Genentech Gets FDA Approval for Lung-Cancer Treatment	Apr. 18	DJ
ROCHE HOLDINGS AG : UBS sticks Neutral	Apr. 18	ZD
Roche’s Multiple Sclerosis Injection Controls Relapses, Brain Lesions in Late-stage Trial	Apr. 17	MT
Roche: positive phase III results in MS	Apr. 17	CF
Roche Holding AG Announces Data from the Phase III OCARINA II Study (S31.006) of OCREVUS®? (ocrelizumab)	Apr. 17	CI
ROCHE HOLDINGS AG : JP Morgan reiterates its Sell rating	Apr. 15	ZD
Roche: positive phase III data in lymphoma	Apr. 15	CF
Roche's Late-stage Trial for Columvi Antibody Meets Primary Survival Endpoint in B-cell Lymphoma	Apr. 15	MT
Roche's Columvi Meets Main Goal in Lymphoma Phase 3 Trial	Apr. 15	DJ
ROCHE HOLDINGS AG : JP Morgan reaffirms its Sell rating	Apr. 12	ZD
Swiss Market Index Falls as ECB Signals June Rate Cut	Apr. 11	MT
ROCHE HOLDINGS AG : Berenberg reiterates its Neutral rating	Apr. 11	ZD
Roche: designation for Alzheimer's test	Apr. 11	CF
Roche, Eli Lilly Alzheimer's Blood Test to Get Expedited FDA Review	Apr. 11	DJ
Roche, Eli Lilly's Elecsys Blood Test Secures US FDA's Breakthrough Device Designation	Apr. 11	MT
Roche Receives FDA Breakthrough Device Designation for Blood Test to Support Early Alzheimer's Disease Diagnosis	Apr. 11	CI
Swiss Market Index Little Changed; Barry Callebaut Shines on Revenue Jump	Apr. 10	MT
Roche’s HER2-Low Metastatic Breast Cancer Diagnostic Test Secures CE Mark	Apr. 10	MT
Roche: CE mark for Enhertu companion test	Apr. 10	CF

Roche Holding AG (Roche) is a research-based healthcare company. The Company's operating businesses are organized into two divisions: Pharmaceuticals and Diagnostics. The Pharmaceuticals Division consists of two business segments: Roche Pharmaceuticals and Chugai. The Diagnostics Division consists of four business areas: Diabetes Care, Molecular Diagnostics, Professional Diagnostics and Tissue Diagnostics. The Company develops medicines for various disease areas, including oncology, immunology, infectious diseases, ophthalmology and neuroscience. Its pharmaceutical products include Anaprox, Avastin, Bactrim, Bondronat, CellCept, Cotellic, Dilatrend, Dormicum, Invirase, Kadcyla, Kytril (Kevatril), Lariam, MabThera, Madopar, Neupogen, Pegasys, Perjeta, Pulmozyme, Rocaltrol, Rocephin and Roferon-A. The Company offers products for researchers, including cell analysis, gene expression, genome sequencing and nucleic acid purification.

Sector

Pharmaceuticals

Calendar

2024-04-24 - Q1 2024 Sales and Revenue Release

Related indices

SMI , STOXX EUROPE 600 (EUR)

More about the company

Income Statement Evolution

More financial data

Analysis / Opinion

ROCHE HOLDING : Q4 miss weighed heavily on the healthy 2024 guidance

February 01, 2024 at 07:42 am EST

Obesity: Roche joins the battle

December 04, 2023 at 10:48 am EST

More Strategies

Ratings for Roche Holding AG

Trading Rating

Investor Rating

ESG Refinitiv

A+

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

HOLD

Number of Analysts

Last Close Price

225.8 CHF

Average target price

281.1 CHF

Spread / Average Target

+24.47%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Pharmaceuticals

	1st Jan change	Capi.
ROCHE HOLDING AG	-6.05%	200B
ELI LILLY AND COMPANY	+27.43%	659B
NOVO NORDISK A/S	+27.68%	557B
JOHNSON & JOHNSON	-4.18%	359B
MERCK & CO., INC.	+16.69%	322B
ABBVIE INC.	+9.82%	297B
ASTRAZENECA PLC	+6.30%	215B
NOVARTIS AG	+4.80%	210B
PFIZER, INC.	-8.84%	149B
AMGEN INC.	-5.04%	146B

Other Pharmaceuticals

Roche Holding AG

Equities

ROG

CH0012032048

Pharmaceuticals

ROCHE HOLDINGS AG : JP Morgan reiterates its Neutral rating

Latest news about Roche Holding AG

Chart Roche Holding AG

Company Profile

Income Statement Evolution

Analysis / Opinion

Ratings for Roche Holding AG

Analysts' Consensus

EPS Revisions

Quarterly earnings - Rate of surprise

Sector Other Pharmaceuticals